CA-VISA-INC.
6.12.2018 14:02:22 CET | Business Wire | Press release
Visa (NYSE:V), the Official Payment Services Partner of FIFA, has announced partnerships with the Union of European Football Associations’ (UEFA) Women’s Football Competitions and the Confederation of African Football (CAF) Total Africa Cup of Nations tournament to evolve its sponsorship portfolio and connect with fans around the world. Leveraging its sponsorship expertise and success at the 2018 FIFA World Cup Russia™, Visa will implement its innovative payment technology at the tournament venues and deliver exclusive experiences for cardholders and clients. By tapping into the strength of the Visa brand and its influential role for fans in football, Visa will help to further elevate women’s football and these regional tournaments.
“Visa has strategically positioned itself at the center of football and these events will further exemplify the unique experiences only Visa can provide to fans across the globe,” said Chris Curtin, chief brand and innovation marketing officer, Visa Inc. “These tournaments allow us distinctive opportunities to showcase Visa’s payment innovation, strengthen partnerships and highlight our evolved offerings to clients and fans.”
Expanding Global Football Portfolio
Visa is partnering with the UEFA Women’s Football Competitions through 2025 to continue its efforts to inspire and empower women, as women’s football continues to grow at all levels. Through its partnership, Visa will collaborate with UEFA for the 2021 Women’s European Championships in the United Kingdom and the annual Women’s Champions League beginning in 2019. Complementing the national team tournament with the world’s finest club competition allows Visa to be at the center of women’s football and strengthens its efforts around diversity, acceptance, and inclusion leading up to the FIFA Women's World Cup France 2019™.
Visa also announced its partnership with CAF as a sponsor of the Total Africa Cup of Nations (AFCON) tournament in 2019 and 2021. The deal will make Visa the exclusive payment services provider at all venues and the official partner of the player escort program. With CAF, Visa will be able to capitalize on football’s popularity throughout the continent, tap into high-growth markets and continue to deliver exclusive benefits to its local communities, clients, partners and fans as they come together to support the best of African football.
Driving Innovation around the Fan Experience
Visa, a FIFA partner since 2007, continues to drive toward new payment innovation that provides fans with faster and enhanced experiences at checkout. Whether it be remote and mobile ticket purchasing, contactless payment technology at transit locations, in-seat ordering or new ways to pay for retail, Visa will utilize its transit, retail and commerce expertise to deliver innovative payments that reimagine the fan experience.
These tournaments present an opportunity for the brand to build upon its success of 2018 FIFA World Cup Russia™. Visa brought contactless payment technology to 12 tournament stadiums and curated unforgettable experiences for more than 250 clients and 3,000 consumers who traveled from over a hundred different countries. In 103 markets around the world, Visa partnered with more than 500 issuers and 40 merchants in 24 languages on a variety of FIFA-related activities, whether to run custom marketing programs, host in-market viewing parties or utilize Visa’s exclusive marketing campaign assets to drive mutual business priorities.
FIFA Women's World Cup France 2019™ Ticket Presale for Visa Cardholders
Following the FIFA Women's World Cup France 2019™ Draw on December 8, Visa will offer an exclusive opportunity for cardholders to be the first fans to purchase individual match tickets for the tournament. The exclusive presale phase will take place from December 10 through December 23 and tickets for all matches will be available. FIFA recently announced that 150,000 FIFA Women's World Cup France 2019™ tickets have been sold since package sales opened in September.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , https://usa.visa.com/visa-everywhere/blog.html and @VisaNews .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005237/en/
Contact:
Visa Inc. Sheerin Salimi shesalim@visa.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom